Compare JQC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | DRUG |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 856.4M |
| IPO Year | N/A | N/A |
| Metric | JQC | DRUG |
|---|---|---|
| Price | $5.06 | $77.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $106.75 |
| AVG Volume (30 Days) | ★ 714.6K | 123.3K |
| Earning Date | 01-01-0001 | 02-10-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.82 | $23.18 |
| 52 Week High | $5.65 | $123.75 |
| Indicator | JQC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 51.49 |
| Support Level | $5.02 | $73.74 |
| Resistance Level | $5.14 | $78.34 |
| Average True Range (ATR) | 0.04 | 4.81 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 10.00 | 59.14 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.